Literature DB >> 18387633

Invasion of tumorigenic HT1080 cells is impeded by blocking or downregulating the 37-kDa/67-kDa laminin receptor.

Chantal Zuber1, Stefan Knackmuss, Georgeta Zemora, Uwe Reusch, Ekaterina Vlasova, Daniela Diehl, Vera Mick, Karin Hoffmann, Daphne Nikles, Thomas Fröhlich, Georg J Arnold, Bertram Brenig, Eckhard Wolf, Harald Lahm, Melvyn Little, Stefan Weiss.   

Abstract

The 37-kDa/67-kDa laminin receptor precursor/laminin receptor (LRP/LR) acting as a receptor for prions and viruses is overexpressed in various cancer cell lines, and their metastatic potential correlates with LRP/LR levels. We analyzed the tumorigenic fibrosarcoma cell line HT1080 regarding 37-kDa/67-kDa LRP/LR levels and its invasive potential. Compared to the less invasive embryonic fibroblast cell line NIH3T3, the tumorigenic HT1080 cells display approximately 1.6-fold higher cell-surface levels of LRP/LR. We show that anti-LRP/LR tools interfere with the invasive potential of HT1080 cells. Anti-LRP/LR single-chain variable fragment antibody (scFv) iS18 generated by chain shuffling from parental scFv S18 and its full-length version immunoglobulin G1-iS18 reduced the invasive potential of HT1080 cells significantly by 37% and 38%, respectively. HT1080 cells transfected with lentiviral plasmids expressing small interfering RNAs directed against LRP mRNA showed reduced LRP levels by approximately 44%, concomitant with a significant decrease in the invasive potential by approximately 37%. The polysulfated glycans HM2602 and pentosan polysulfate (SP-54), both capable of blocking LRP/LR, reduced the invasive potential by 20% and 35%, respectively. Adhesion of HT1080 cells to laminin-1 was significantly impeded by scFv iS18 and immunoglobulin G1-iS18 by 60% and 68%, respectively, and by SP-54 and HM2602 by 80%, suggesting that the reduced invasive capacity achieved by these tools is due to the perturbation of the LRP/LR-laminin interaction on the cell surface. Our in vitro data suggest that reagents directed against LRP/LR or LRP mRNA such as antibodies, polysulfated glycans, or small interfering RNAs, previously shown to encompass an anti-prion activity by blocking or downregulating the prion receptor LRP/LR, might also be potential cancer therapeutics blocking metastasis by interfering with the LRP/LR-laminin interaction in neoplastic tissues.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18387633     DOI: 10.1016/j.jmb.2008.02.004

Source DB:  PubMed          Journal:  J Mol Biol        ISSN: 0022-2836            Impact factor:   5.469


  28 in total

Review 1.  Structure-guided identification of a laminin binding site on the laminin receptor precursor.

Authors:  Kelly V Jamieson; Stevan R Hubbard; Daniel Meruelo
Journal:  J Mol Biol       Date:  2010-10-30       Impact factor: 5.469

2.  Failure-to-thrive syndrome associated with tumor formation by Madin-Darby canine kidney cells in newborn nude mice.

Authors:  Lauren R Brinster; Romelda L Omeir; Gideon S Foseh; Juliete N Macauley; Philip J Snoy; Joel J Beren; Belete Teferedegne; Keith Peden; Andrew M Lewis
Journal:  Comp Med       Date:  2013-08       Impact factor: 0.982

3.  Monoclonal antibodies specific for oncofetal antigen--immature laminin receptor protein: Effects on tumor growth and spread in two murine models.

Authors:  Shannon D McClintock; Roscoe L Warner; Saqib Ali; Apurupa Chekuri; Michael K Dame; Durga Attili; Randall K Knibbs; Muhammad Nadeem Aslam; Joseph Sinkule; Alton Charles Morgan; Adel Barsoum; Lauren B Smith; David G Beer; Kent J Johnson; James Varani
Journal:  Cancer Biol Ther       Date:  2015       Impact factor: 4.742

4.  Chemical inhibition of prometastatic lysyl-tRNA synthetase-laminin receptor interaction.

Authors:  Dae Gyu Kim; Jin Young Lee; Nam Hoon Kwon; Pengfei Fang; Qian Zhang; Jing Wang; Nicolas L Young; Min Guo; Hye Young Cho; Ameeq Ul Mushtaq; Young Ho Jeon; Jin Woo Choi; Jung Min Han; Ho Woong Kang; Jae Eun Joo; Youn Hur; Wonyoung Kang; Heekyoung Yang; Do-Hyun Nam; Mi-Sook Lee; Jung Weon Lee; Eun-Sook Kim; Aree Moon; Kibom Kim; Doyeun Kim; Eun Joo Kang; Youngji Moon; Kyung Hee Rhee; Byung Woo Han; Jee Sun Yang; Gyoonhee Han; Won Suk Yang; Cheolju Lee; Ming-Wei Wang; Sunghoon Kim
Journal:  Nat Chem Biol       Date:  2013-11-10       Impact factor: 15.040

5.  Comprehensive proteomic analysis of nonintegrin laminin receptor interacting proteins.

Authors:  Lisa Venticinque; Daniel Meruelo
Journal:  J Proteome Res       Date:  2012-08-29       Impact factor: 4.466

6.  Characterization of the ovine ribosomal protein SA gene and its pseudogenes.

Authors:  Alice Van den Broeke; Mario Van Poucke; Ane Marcos-Carcavilla; Karine Hugot; Hélène Hayes; Maud Bertaud; Alex Van Zeveren; Luc J Peelman
Journal:  BMC Genomics       Date:  2010-03-16       Impact factor: 3.969

7.  Anti-LRP/LR specific antibody IgG1-iS18 significantly impedes adhesion and invasion in early and late stage colorectal carcinoma cells.

Authors:  Leila Vania; Carryn J Chetty; Eloise Ferreira; Stefan F T Weiss
Journal:  Mol Med       Date:  2016-09-08       Impact factor: 6.354

8.  Multiple functions of the 37/67-kd laminin receptor make it a suitable target for novel cancer gene therapy.

Authors:  Jonathan Scheiman; Jen-Chieh Tseng; Yun Zheng; Daniel Meruelo
Journal:  Mol Ther       Date:  2009-09-01       Impact factor: 11.454

9.  Adhesion and Invasion of Breast and Oesophageal Cancer Cells Are Impeded by Anti-LRP/LR-Specific Antibody IgG1-iS18.

Authors:  Thandokuhle Khumalo; Uwe Reusch; Stefan Knackmuss; Melvyn Little; Robin B Veale; Stefan F T Weiss
Journal:  PLoS One       Date:  2013-06-18       Impact factor: 3.240

10.  In vitro inhibition of angiogenesis by antibodies directed against the 37kDa/67kDa laminin receptor.

Authors:  Raksha Khusal; Bianca Da Costa Dias; Kiashanee Moodley; Clement Penny; Uwe Reusch; Stefan Knackmuss; Melvyn Little; Stefan F T Weiss
Journal:  PLoS One       Date:  2013-03-12       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.